Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
A Phase 2 Safety, Dose-finding and Efficacy Study Evaluating Viscoelastic Testing (VET) Guided Tissue Plasminogen Activator (tPA) Treatment in Critically-ill Pro-thrombotic Acute Respiratory Failure
South West Sydney Local Health District
70 participants
May 18, 2022
INTERVENTIONAL
Conditions
Summary
Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.
Eligibility
Inclusion Criteria5
- Acute respiratory failure of primary pulmonary infectious or extrapulmonary infectious aetiology with severity graded by the arterial oxygen partial pressure to inspired fraction of oxygen ratio (P/F) as per the Berlin definition: acute onset of hypoxemia with an arterial partial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2) ratio of less than or equal to 300 mmHg with positive end expiratory pressure (PEEP) of 5 cm of water (H2O) or greater
- Requiring admission to Intensive Care
- Aged 18 - 75 years of age
- Procoagulant profile on ClotPro (TradeMark) fibrinogen (FIB)-test +/- extrinsic coagulation pathway (EX)-test - above normal range for amplitude at 10 minutes (A10) and/or maximal clot firmness (MCF) at 30 minutes run time
- Lysis Time on ClotPro tissue plasminogen activator (TPA)-test ClotPro equal to or greater than 365 seconds
Exclusion Criteria20
- Platelet count <150 x 109/L or a reduction in platelet count of 50% or more in the last 24 hours
- Body weight < 60 kg
- Structural intracranial disease e.g. arterio-venous malformation or aneurysm
- Previous intracranial haemorrhage
- Ischaemic stroke within 3 months
- Traumatic cardiopulmonary resuscitation
- Hypoxaemia from traumatic lung injury
- Active or recent bleeding
- Recent surgery, trauma or invasive procedure
- Systolic blood pressure (BP) > 180 mm Hg
- Diastolic BP > 100 mm Hg
- Pericarditis or pericardial fluid
- Diabetic retinopathy
- Currently menstruating
- Pregnancy - (beta-human chorionic gonadotropin (HCG) to be performed if of child-bearing age)
- Liver failure (known severe liver disease or an alanine aminotransferase or an aspartate aminotransferase level that is 5 times the upper limit of normal)
- Kidney failure (estimated Glomerular Filtration Rate (eGFR =<30 mL/hr or receiving renal replacement therapy)
- Use of therapeutic anticoagulation or platelet antagonists
- Not for active treatment
- Unlikely to survive until the day after tomorrow
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05540834